Resmed Inc’s recent filing unveils that its Director Hernandez John acquired Company’s shares for reported $0.74 million on Aug 18 ’25. In the deal valued at $287.10 per share,2,575 shares were bought.
Then, Farrell Michael J. sold 8,009 shares, generating $2,238,379 in total proceeds. Upon selling the shares at $279.48, the Chief Executive Officer now owns 455,503 shares.
Before that, Farrell Michael J. bought 8,009 shares. Resmed Inc shares valued at $2,265,185 were divested by the Officer at a price of $282.83 per share.
RBC Capital Mkts upgraded its Resmed Inc [RMD] rating to an Outperform from a a Sector perform in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in mid March with a ‘”an Overweight”‘ rating. Morgan Stanley began covering RMD with “an Overweight” recommendation on March 19, 2025. Goldman started covering the stock on January 16, 2025. It rated RMD as “a Buy”.
Price Performance Review of RMD
On Monday, Resmed Inc [NYSE:RMD] saw its stock jump 0.43% to $286.12. Over the last five days, the stock has gained 0.63%. Resmed Inc shares have risen nearly 28.76% since the year began. Nevertheless, the stocks have risen 25.11% over the past one year. While a 52-week high of $293.08 was reached on 08/04/25, a 52-week low of $199.92 was recorded on 04/07/25.
Levels Of Support And Resistance For RMD Stock
The 24-hour chart illustrates a support level at 284.42, which if violated will result in even more drops to 282.71. On the upside, there is a resistance level at 287.83. A further resistance level may holdings at 289.53.
How much short interest is there in Resmed Inc?
A steep rise in short interest was recorded in Resmed Inc stocks on 2025-07-31, dropping by -1.11 million shares to a total of 9.02 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 10.13 million shares. There was a decline of -12.28%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 10, 2025 when Piper Sandler began covering the stock and recommended ‘”a Neutral”‘ rating along with a $252 price target.
